Objective: To determine the efficacy, safety and tolerability of cetilistat (ATL-962), a novel inhibitor of gastrointestinal (GI) lipases, in obese patients. Design: Phase II, multicentre, randomized, placebo-controlled, parallel group study. Enrolled patients (N ¼ 442) were advised a hypocaloric diet (deficient by 500 kcal per day, 30% of calories from fat) for a 2-week run-in period. Patients who satisfied the entry criteria (N ¼ 371) continued on the hypocaloric diet and were randomized to either placebo or one of three different doses of cetilistat (60 mg three times daily t.i.d., 120 mg t.i.d. and 240 mg t.i.d.) for 12 weeks, followed by a 4-week post-treatment follow-up. Safety, tolerability and body weight were assessed, together with other parameters associated with obesity. Outcome measures: The primary outcome measure was absolute change in body weight from baseline. Secondary outcomes included the proportion of patients achieving pre-defined weight loss targets, changes from baseline in waist circumference and in blood lipids. GI tolerability criteria were specifically assessed, as was safety. Results: Treatment with cetilistat reduced mean body weight to similar extents at all doses, which were statistically significant compared with placebo (60 mg t.i.d. 3.3 kg, Po0.03; 120 mg t.i.d. 3.5 kg, P ¼ 0.02; 240 mg t.i.d. 4.1 kg, Po0.001). Total serum and low-density lipoprotein cholesterol levels were likewise significantly reduced by 3-11% at all doses of cetilistat. Cetilistat was well tolerated. The frequency of withdrawal owing to treatment-emergent adverse events was similar between cetilistat-treated groups (5.3-7.6%) and placebo (7.6%). Adverse events were generally mild to moderate in intensity, occurred on only one occasion and were mostly GI in nature. The incidence of GI adverse events was increased in the cetilistat-treated groups compared to placebo. However, those GI adverse events, such as flatus with discharge and oily spotting, only occurred in 1.8-2.8% of subjects in the cetilistat-treated groups. Conclusions: Cetilistat produced a clinically and statistically significant weight loss in obese patients in this short-term 12-week study. This was accompanied by significant improvements in other obesity-related parameters. Cetilistat treatment was well tolerated. The risk-benefit demonstrated in this study in terms of weight loss vs intolerable GI adverse effects shows that cetilistat merits further evaluation for the pharmacotherapy of obesity and related disorders.
Introduction
Obesity is a growing public health problem, and in many countries it has reached epidemic proportions. 1 It is a complex multifactorial disorder characterized by an excess accumulation of adipose tissue, and is associated with increased risks for a number of complications, including type 2 diabetes, cardiovascular disease, hypertension, dyslipidemia and cancer. [2] [3] [4] A sustained weight loss of between 5
and 10% of initial body weight has been associated with clinically meaningful reductions in these obesity-related comorbidities. [5] [6] [7] Effective pharmacotherapies that can produce sustained weight loss of this magnitude, when accompanied by an acceptable adverse effect profile are urgently needed.
One approach is to induce a negative energy balance by targeting fat metabolism and gastrointestinal (GI) lipases in particular. Inhibition of lipases reduces hydrolysis of dietary triglycerides, limiting the absorption of monoglycerides and free fatty acids, thereby enhancing weight loss.
Orlistat (Xenical), an inhibitor of GI lipases approved for use in the long-term management of obesity and associated co-morbidities in adults and adolescents, can be associated with a number of undesirable GI-related adverse events. These include oily spotting, flatus with discharge, oily evacuation and faecal incontinence, which can reduce patient compliance and withdrawal from treatment. [8] [9] [10] Cetilistat is a novel highly lipophilic benzoxazinone that inhibits GI and pancreatic lipases, which raises the possibility of a distinct clinical profile, and is in development for the management of obese patients with or without complications. In Phase I clinical trials in healthy volunteers, cetilistat increased faecal fat excretion and was well tolerated. GI adverse events were predominantly oily stool, and the number of volunteers who experienced 41 episode was 11% (n ¼ 66). There was no correlation between the level of faecal fat excretion and the incidence of oily stool. 11 We present the results of a Phase II, placebo-controlled, randomized, multi-centre 12-week study designed to investigate the efficacy, tolerability and safety of three different doses of cetilistat.
Patients and methods

Patients
Male and female obese patients aged between 18 and 65 years were included in this study (Table 1) . Obesity was defined as a body mass index (BMI) of X30 kg/m 2 and no co-morbidities, or a BMI of 428 kg/m 2 with established co-morbidities, that is, diabetes or hypertension or hypercholesterolaemia, that did not require pharmaceutical intervention.
Study design
A multi-centre, randomized, double-blind, placebo-controlled, parallel group study, conducted at 20 centres in five countries, comprising a 2-week run-in, 12 weeks of treatment, and a 4-week post-treatment follow-up. From the start of the run-in period, patients were advised to follow a diet that for each subject was deficient by approximately 500 kcal per day, and provided approximately 30% of calorie intake as fat. Patients gaining weight during the run-in period (n ¼ 10) were excluded from the study. All other patients meeting the inclusion criteria (n ¼ 371) were randomized in a 1:1:1:1 ratio to receive cetilistat (60, 120, 240 mg) or placebo three times daily (t.i.d.) with food for 12 weeks. Clinic assessments together with dietary reinforcement were made every 4 weeks and additional telephone contacts were made approximately 2 weeks after each clinic visit. Ethical approval was obtained for the trial from the relevant regulatory authorities and independent ethical review boards. All patients provided written informed consent before entry into the trial. The study protocol was reviewed and approved by central or local independent ethics committees in accordance with applicable national regulations.
Assessments
The primary efficacy variable was the absolute reduction in body weight from baseline (taken as randomization). Secondary efficacy assessments included the proportion of patients achieving weight loss within pre-defined limits (40-o5%, 5-10% or 410%), and change from baseline in waist circumference, blood pressure, fasting blood glucose, insulin and HbA 1c levels, and serum lipid profile. Safety assessments included physical examination, vital signs, 12-lead electrocardiogram (ECG), laboratory variables including haematology, blood chemistry and adverse events, including a detailed assessment of specific GI adverse events. Cetilistat (ATL-962), a novel lipase inhibitor P Kopelman et al
Statistical analysis
The primary analyses of efficacy variables were performed using the intent-to-treat population, which comprised all randomized patients who received at least one dose of study medication and who had at least one post-baseline weight assessment. In cases of missing data, the last observation carried forward was used. Analysis of weight change data was performed using analysis of variance (ANOVA), with weight change as the response and treatment and centre as fixed effects. Least square (LS) mean values with 95% confidence intervals for the LS mean difference were also calculated and used to determine the placebo-adjusted effect of cetilistat. Based on the ANOVA results, Dunnett's post hoc test for multiple comparisons was used to compare differences in absolute weight loss between the three active treatment groups and the placebo group. Changes from baseline in BMI, waist circumference, blood pressure, fasting blood glucose, insulin, HbA 1c levels and serum lipid profile were also analysed using ANOVA, with treatment and centre as fixed effects. For all end points, a value of Po0.05 was considered statistically significant.
Results
Patients
Of the 442 patients who entered screening, a total of 371 patients were randomized and received study drug. Of the randomized patients, 76 (20.4%) discontinued prematurely, distributed evenly across all treatment groups: adverse events (7.0%); withdrawal of consent (6.0%); lost to follow-up (4.8%); protocol violation (2.7%) and other reasons (0.5%).
The baseline characteristics of the randomized patients are presented in Table 1 . The mean age of the study population was 41.6 years (range: 19-64 years), and 76% of patients were female.
Efficacy
During the 2-week run-in, bodyweight was reduced by 1.7, 1.7, 1.7 and 1.9 kg for placebo, cetilistat 60, 120 and 240 mg, respectively.
Treatment with cetilistat at all three doses for 12 weeks produced significantly greater absolute weight loss compared to placebo, with the effect of cetilistat being similar for all the doses studied ( Figure 1) . The proportion of patients achieving at least a 5% reduction in baseline weight ( Figure 2 ) and in waist circumference (60 mg À3.4 cm; 120 mg À3.7 cm; 240 mg À4.2 cm; placebo À2.4 cm) was greater in all three active treatment groups relative to placebo.
Cetilistat caused a significant reduction (6-11%) in serum low-density lipoprotein (LDL) cholesterol and in serum total cholesterol (3-8%) at all doses ( Table 2 ). The effect of cetilistat on high-density lipoprotein (HDL)-cholesterol was less marked (Table 2 ). There were no significant differences between placebo and cetilistat at any dose in: serum triglyceride levels, fasting blood glucose, insulin, HbA 1c level, mean systolic and mean diastolic blood pressure which remained in the normal range throughout the study for all treatment groups (not shown).
Safety and tolerability
The frequency of withdrawals owing to treatment-emergent adverse events was low (7.0% overall), and was similar in both the placebo (7.6%) and cetilistat treatment groups (60 mg t.i.d. 7.5%, 120 mg t.i.d. 7.6%, 240 mg t.i.d. 5.3%). Serious adverse events were experienced by 2.7% (10/371) of patients, distributed equally across all four treatment groups.
Treatment-emergent adverse events were experienced by 82.5% (306/371) of patients. The proportion of patients (195) . The majority (96%) of adverse events were mild to moderate in intensity, and there was no treatment-related difference in the severity of specific adverse events. The most frequently experienced adverse events were those involving the GI tract. The proportion of patients and the total number of GI adverse events reported in each of the active treatment groups were higher compared to the placebo group. However, GI adverse events were predominantly mild to moderate in intensity, with no evidence of a dose relationship. The most frequently reported GI-related adverse events included increased defecation (25.8% on cetilistat vs 6.5% on placebo), soft stools (28.0 vs 7.6%), abdominal pain (19.3 vs 8.7%), flatulence (16.8 vs 10.9%) and fatty/oily stool (13.6 vs 1.1%), which were all reported more frequently in the treatment arms compared to the placebo arm. Faecal incontinence, flatus with discharge, oily evacuation and oily spotting occurred in only 1.8-2.8% of subjects in the active treatment arms and was not dose-related. Adverse events generally occurred on only one occasion and resolved rapidly. There were no significant changes in routine laboratory parameters, physical examination findings, heart rate or ECG. Serum vitamin D, vitamin E and b-carotene levels (Table 2) were decreased significantly in the cetilistat treatment arms. Generally, these reductions in vitamin levels did not take the levels outside the normal range and none required the use of vitamin supplements. There were no significant changes in serum vitamin A levels, or prothrombin time.
Discussion
The results from this randomized, placebo-controlled, 12-week Phase II study demonstrate that treatment with the novel GI lipase inhibitor cetilistat produces a clinically significant absolute weight loss relative to placebo in obese patients on a hypocaloric moderate fat (30%) diet. Results from the secondary efficacy outcome measures provide further support for the benefits of cetilistat treatment in the reduction of obesity-related risk factors. The effects of cetilistat on weight loss increased over the study duration, suggesting that continued treatment could lead to further and sustained weight loss; this is consistent with other pharmacotherapies.
The magnitude of absolute weight loss observed over this treatment period was comparable to that reported for orlistat, [8] [9] [10] 12 ,13 sibutramine 14,15 and rimonabant. 16, 17 The magnitude of absolute weight loss in the placebo group was similar to that reported for orlistat trials, but greater than that in sibutramine and rimonabant trials, which reflects the greater dietary support given to patients in the lipase inhibitor studies. These data indicate that pharmacotherapy produces similar absolute weight loss, regardless of the mechanism of action of the agent concerned. Cetilistat (ATL-962), a novel lipase inhibitor P Kopelman et al Treatment with cetilistat also had a beneficial effect on the factors commonly associated with the risk of obesity-related co-morbidities. Modest reductions in bodyweight (5-10%) have been shown to improve glycaemic control, 18 hypertension 6 and cardiovascular disease risk. 19 Approximately 30% of patients in each treatment group achieved a weight loss of at least 5% after 12 weeks, compared to 17% in the placebo group. The reductions in waist circumference observed with cetilistat suggest that weight loss observed here is accompanied by a reduction in visceral fat, and therefore potentially a corresponding decrease in cardiovascular disease risk. Cetilistat significantly reduces total serum cholesterol and LDL-cholesterol. Interestingly, the reduction in these parameters appeared to be dose-related, as was the proportion of subjects losing 45% of body weight, whereas the overall weight reduction observed was similar across all groups. This is probably coincidental and reflects the wide variances in these secondary end points in this short-term study. Alternatively, it may indicate that reduction in these values is not absolutely related to weight loss over a relatively short treatment period. It has been demonstrated that significant increases in HDL-cholesterol are only observed when body weight has been stabilized for a period of time. 20 This explains why the effect of cetilistat on HDL-cholesterol was less marked. Cetilistat was well tolerated, with most adverse events being of mild to moderate intensity and comparable to placebo. The frequency of serious adverse events, and the withdrawal from treatment owing to adverse event rate, was no greater in any of the active treatment groups relative to placebo. The majority of treatment-emergent adverse events observed in this study involved the GI system, consistent with data from Phase I studies with cetilistat. 11 Given that lipase inhibitors such as cetilistat increase faecal fat content through their mode of action, it has been suggested that the GI-related adverse events observed are a class effect. However, Phase I dose escalation studies with cetilistat have shown that increases in faecal fat content do not appear to be correlated with an increased incidence of oily stool, a common adverse event. 11 These data, coupled with those from this study, suggest that increase in GI adverse events is not necessarily a class effect related to increased fat in the bowel.
There was a modest reduction in the levels of fat-soluble vitamins (D and E) and b-carotene, although they were generally within the normal range and no patient required supplemental vitamins.
In conclusion, treatment with cetilistat for 12 weeks in combination with a reduced fat, hypocaloric diet in obese patients produces a clinically and statistically significant absolute weight loss, supported by improvements in BMI, waist measurement and total cholesterol and LDL-cholesterol levels. Cetilistat shows a good safety and tolerability profile, particularly GI tolerability. Further longer-term clinical trials, including a direct comparison with orlistat, to confirm the benign adverse event profile observed to date, are therefore warranted.
